3 Promising Penny Stocks With Market Caps Up To $200M

Over the last 7 days, the U.S. market has dropped 2.6%, but it has risen by 14% over the past year, with earnings projected to grow annually by 17% in the coming years. In light of these conditions, investors may find value in penny stocks—an investment area that still holds relevance despite being an older term. By focusing on companies with solid financials and potential for growth, investors can uncover opportunities among smaller or less-established firms that might offer both stability and upside potential.

We're going to check out a few of the best picks from our screener tool.

KORU Medical Systems (KRMD)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: KORU Medical Systems, Inc. develops, manufactures, and commercializes subcutaneous infusion solutions for the drug delivery market both in the United States and internationally, with a market cap of $184.19 million.

Operations: The company's revenue is derived from its Surgical & Medical Equipment segment, which generated $43.26 million.

Market Cap: $184.19M

KORU Medical Systems, with a market cap of US$184.19 million, focuses on subcutaneous infusion solutions and reported first-quarter 2026 sales of US$11.76 million, up from US$9.64 million the previous year, while reducing its net loss to US$0.81 million from US$1.17 million. The company is debt-free and maintains a stable cash runway for over three years due to positive free cash flow growth of 4.7% annually despite being unprofitable with a negative return on equity (-13.47%). Recent product presentations highlighted high satisfaction rates among nurses and patients using their infusion systems at oncology centers across the U.S., supporting future revenue growth projections between $47.5-$50 million for 2026 with gross margins expected between 61%-63%.

• Dive into the specifics of KORU Medical Systems here with our thorough balance sheet health report.
• Understand KORU Medical Systems' earnings outlook by examining our growth report.

Planet Image International (YIBO)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Planet Image International Limited manufactures and sells compatible toner cartridges through its own brands or third-party brands via online retail platforms globally, with a market cap of $74.64 million.

Operations: The company's revenue is primarily derived from its Printers & Related Products segment, totaling $155.25 million.

Market Cap: $74.64M

Planet Image International, with a market cap of US$74.64 million, focuses on compatible toner cartridges and generates US$155.25 million in revenue from its Printers & Related Products segment. Despite being unprofitable with a negative return on equity of -14.25%, the company has reduced its debt to equity ratio significantly over five years and holds more cash than total debt, though operating cash flow remains negative. Short-term assets surpass both short-term and long-term liabilities, indicating solid liquidity management despite high weekly share price volatility at 15%. The board is experienced with an average tenure of 5.1 years.

• Click here to discover the nuances of Planet Image International with our detailed analytical financial health report.
• Evaluate Planet Image International's historical performance by accessing our past performance report.

Zevia PBC (ZVIA)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Zevia PBC develops, markets, sells, and distributes zero sugar beverages in the United States and Canada with a market cap of approximately $123.94 million.

Operations: The company's revenue is derived entirely from its non-alcoholic beverages segment, totaling $169.33 million.

Market Cap: $123.94M

Zevia PBC, with a market cap of US$123.94 million, focuses on zero sugar beverages and reported US$169.33 million in revenue. The company remains unprofitable with a negative return on equity of -20.97% and has experienced significant index removals recently, impacting its visibility to investors. Despite this, Zevia's short-term assets exceed its liabilities by a healthy margin, providing liquidity stability. The management team is relatively new but led by Alexandre Ruberti, who brings extensive experience from the beverage industry. Shareholders have not faced significant dilution recently and the company is debt-free with a sufficient cash runway for over three years based on current free cash flow trends.

• Click here and access our complete financial health analysis report to understand the dynamics of Zevia PBC.
• Gain insights into Zevia PBC's outlook and expected performance with our report on the company's earnings estimates.

Where To Now?

• Investigate our full lineup of 339 US Penny Stocks right here.
• Curious About Other Options? The end of cancer? These 33 emerging AI stocks are developing tech that will allow early idenification of life changing disesaes like cancer and Alzheimer's.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com